1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Eris Lifesciences Ltd

Eris Lifesciences Ltd

1,121.60
INR
-13.95
(-1.23%)
48.56EPS
30.57P/E
199.21BMarket Cap
Oct 26Next Earn
Eris Lifesciences Ltd
BSE:ERIS
(Bombay Stock Exchange)

Recent

price

1,121.60

P/E

ratio

30.57

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
28.59
37.01
39.68
43.42
54.51
60.15
70.33
77.13
87.84
97.6
122.21
146.4
211.56
227.9
234.6
Revenue per Share
4.23
5.12
6.49
9.71
17.95
21.39
21.15
21.61
26.16
29.89
28.1
28.82
25.85
45.33
47.03
Basic EPS, GAAP
2.19
2.74
5.6
7.84
10.94
15.24
13.45
8.74
25.75
18.93
-40.42
26.24
66.87
17.64
- -
Free Cash Flow per Basic Share
- -
- -
- -
6.04
1.23
- -
- -
3.42
5.5
6.01
7.35
- -
7.35
- -
- -
Dividend per Share
7.72
12.84
19.32
23.33
41.25
62.64
83.66
95.47
116.1
140.39
161.48
190.12
209.63
281.69
- -
Book Value per Share
7.47
12.55
19.01
23.28
25.7
10.39
32.24
37.15
58.84
84.99
-1.21
-87.8
-131.48
-41.61
- -
Tangible Book Value per Share
138
138
138
138
138
138
138
137
136
136
136
136
136
137
137
Basic Weighted Avg Shares
3,931
5,088
5,456
5,970
7,495
8,271
9,672
10,582
11,926
13,262
16,618
19,913
28,793
31,149
32,124
Sales/Revenue/Turnover
22.04
18.53
19.42
25.82
32.9
35.85
32.15
30.57
32.6
32.05
25.41
24.88
24.43
27.01
26.73
Operating Margin (%)
35
48
155
204
228
256
364
503
430
647
1,171
1,825
3,155
2,795
2,811
Depreciation Expense
582
704
892
1,336
2,468
2,941
2,908
2,965
3,551
4,061
3,822
3,921
3,518
6,195
6,439
Net Income, GAAP
29.71
28.26
18.42
12.68
8.79
5.53
8.26
10.52
9.98
8.23
7.53
7.93
23.36
- -
- -
Effective Tax Rate (%)
14.81
13.84
16.36
22.37
32.93
35.56
30.07
28.02
29.78
30.62
23
19.69
12.22
19.89
20.04
Profit Margin (%)
828
838
976
903
1,402
732
2,762
3,149
3,001
4,277
3,215
-2,300
-1,584
-5,372
- -
Working Capital
6
- -
5
- -
5
2,742
3
61
44
804
6,834
6,915
17,817
9,960
- -
LT Debt
1,108
1,809
2,696
3,240
5,909
8,860
11,688
12,963
15,764
19,082
22,207
32,221
32,718
38,957
- -
Total Equity
- -
45.84
38.25
43.17
48.31
30.13
21.82
21.51
24.13
21.65
15.25
9.95
9.14
- -
- -
Return on Invested Capital (%)
- -
47.81
39.48
44.49
54.12
32.7
23.88
22.49
24.67
22.95
16.28
10.22
8.62
- -
- -
Return on Capital (%)
- -
49.84
40.36
45.55
55.58
41.18
28.91
24.23
24.72
23.31
18.62
16.4
12.93
18.34
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
13,626
- -
LT Borrowings
- -
9,558
- -
LT Finance Leases
- -
402
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
136
139
139
Market Capitalization
204,843
179,856
199,207

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
15,399
- -
Cash, Cash Equivalents & STI
- -
554
- -
Accounts Receivable, Net
- -
6,803
- -
Inventories
- -
4,368
- -
Total Current Liabilities
- -
20,771
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
13,626
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.99%
20.63%
19.07%
Free Cash Flow
-20%
-84.7%
-73.5%
Net Income, GAAP
20.14%
15.37%
76.08%
Sales/Revenue/Turnover
18.41%
21.82%
8.18%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
7,156
7,390
7,221
7,026
28,793
2026
7,716
7,902
8,009
7,523
31,149
2027
8,690
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
6.11
6.73
6.15
6.9
25.85
2026
8.66
8.82
7.32
20.6
45.33
2027
10.28
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
7.35
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Eris Lifesciences Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and marketing of branded formulations focused on chronic and sub-chronic therapies including anti-diabetes, cardiovascular, nutrition, dermatology, neuroscience, neuropsychiatry, oncology, critical care, nephrology, gynaecology, and insulins. The company offers a portfolio of over 200 branded products such as Eritel, Glimsave, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Remylin, Zomelis, Crevast, Atorsave, Ginkocer, and Metital, alongside sterile injectables and biosimilars; it operates manufacturing facilities in Gujarat and Guwahati and distributes through a network covering India and over 100 countries in regions including Asia Pacific, Africa, Middle East, Latin America, Europe, and the United States. Founded in 2007 and headquartered in Ahmedabad, Gujarat, Eris Lifesciences targets physicians and healthcare providers in the domestic branded formulations market while expanding internationally via exports and partnerships. Recent major developments include the 2024 acquisition of Biocon Biologics' branded formulations business in India for INR 1,242 crore, encompassing insulin brands Basalog and Insugen, critical care products like immunoglobulins and ICU antibiotics, and oncology monoclonal antibodies such as Nimotuzumab, alongside a prior acquisition of Biocon's nephrology and dermatology units for INR 366 crore; the company also acquired a 70% controlling stake in Swiss Parenterals Limited for INR 875 crore to enter the sterile injectables market with over 190 molecules and a pipeline of 40 more, plus earlier entries into insulins via a JV with MJ Biopharm and dermatology through Oaknet Healthcare and brands from Glenmark and Dr. Reddy's.